Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.
Explore this paper's citation graph
Summary
Eblotinib may produce clinical benefits in patients who had shown long SD on prior gefitinib therapy and EGFR mutations were not positive predictors for erlotinib response after gefITinib failure.
- Type
- article
- Published
- 2010-04-01
- Cited by
- 66
- References
- 33
- OpenAlex
- https://openalex.org/W2047665602
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:44003361
Keywords
Erlotinib, Gefitinib, Medicine, Rash, Internal medicine
References
- Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
- Epidermal growth factor receptor mutations in lung cancer
- Erlotinib in lung cancer - molecular and clinical predictors of outcome.
- Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
- EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
- Three Cases of Long-Lasting Tumor Control with Erlotinib after Progression with Gefitinib in Advanced Non-Small Cell Lung Cancer
- Erlotinib after Failure of Gefitinib in Patients with Advanced Non-small Cell Lung Cancer Previously Responding to Gefitinib
- Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
- Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma.
- Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash.
- Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
- Evidence for Disease Control with Erlotinib after Gefitinib Failure in Typical Gefitinib-Sensitive Asian Patients with Non-small Cell Lung Cancer
- Anticancer drugs: To the rescue?
- Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
- Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
- First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
- BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
- Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
- Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Cited by
- Recurrence patterns of advanced non‐small cell lung cancer treated with gefitinib
- La Ultrasonografia endobronquial per a l'estudi del mediastí
- 既往吉非替尼治疗获益的晚期NSCLC患者再次使用EGFR-TKI的选择：原药还是换药？
- Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment
- EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
- 酪氨酸激酶抑制剂耐药机制及其治疗策略
- 晚期非小细胞肺癌初始治疗后再次应用EGFR-TKI的疗效观察
- Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor
- A case of lung adenocarcinoma with postoperative recurrence of multiple bone metastases that showed a gradual complete response to combined administration of erlotinib and zoledronic acid.
- Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
- Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer
- 五次应用分子靶向药物治疗晚期肺癌患者1例
- Salvage treatment with erlotinib after gefitinib failure in advanced non‐small‐cell lung cancer patients with poor performance status: A matched‐pair case–control study
- AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
- Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies
- Readministration of EGFR Tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients after Initial Failure, What Affects its Efficacy?
- Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
- The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib
- Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer
- Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma.
Related papers
- Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
- Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
- Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
- Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
- Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer
- The effect of erlotinib on EGFR and downstream signaling in oral cavity squamous cell carcinoma
- Sequential responses of adenocarcinoma of the lung to erlotinib after gefitinib in never smoker Korean woman.
- Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
- A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
- Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib